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Abstract
Background:  The transcription factor Yin Yang 1 (YY1) is a ubiquitously expressed,
multifunctional protein that controls a large number of genes and biological processes in
vertebrates. As a general transcription factor, the proper levels of YY1 protein need to be
maintained for the normal function of cells and organisms. However, the mechanism for the YY1
homeostasis is currently unknown.
Results: The current study reports that the YY1 gene locus of all vertebrates contains a cluster of
its own DNA-binding sites within the 1st intron. The intact structure of these DNA-binding sites is
absolutely necessary for transcriptional activity of the YY1 promoter. In an inducible cell line
system that over-expresses an exogenous YY1 gene, the overall increased levels of YY1 protein
caused a reduction in transcription levels of the endogenous YY1 gene. Reversion to the normal
levels of YY1 protein restored the transcriptional levels of the endogenous YY1 to normal levels.
This homeostatic response was also mediated through its cluster of YY1 binding sites.
Conclusion: Taken together, the transcriptional level of YY1 is self-regulated through its internal
DNA-binding sites. This study identifies YY1 as the first known autoregulating transcription factor
in mammalian genomes.
Background
The Gli-Kruppel-type transcription factor Yin Yang 1 (YY1)
is a ubiquitously expressed, multifunctional protein that
can function as an activator, repressor, or initiator binding
protein depending on its promoter context, chromatin
structure, and interacting proteins [1,2]. YY1 is also
known to undergo various post-translational modifica-
tions, causing different outcomes on the functions of YY1.
YY1 interacts directly or indirectly with many key proteins
including the components of 1) RNA polymerase II tran-
scription machineries, such as RNA polymerase II, TFIIB,
TBP and TAFII55, 2) transcription factors, such as Sp1, c-
myc, c-myb and CREB, and 3) histone-modifying com-
plexes, such as p300, CBP, HATs, HDACs, PRMT1, and
PhoRC and INO80 [3,4].
YY1 is involved in the transcriptional control of a large
number of mammalian genes, approximately 10% of the
total mammalian gene set [5]. Consequently, YY1 plays
important roles in a number of biological processes,
including cell cycle control, embryogenesis, viral infec-
tion, programmed cell death, oncogenesis, Polycomb
Group (PcG) function and B-cell development [6]. Since
it is a general transcription factor involved in so many
pathways, the expression levels of YY1 must be tightly
monitored for the survival of cells and organisms [4].
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Accordingly, abnormal YY1 protein levels have been
shown to cause defects in cell proliferation and differenti-
ation, neural development, and the repression mediated
by the PcG complex. Also, there are several types of the
YY1-related diseases, such as viral infection and cancers,
which are also linked to abnormal YY1 protein levels [3].
These observations clearly predict the presence of some
regulatory mechanism(s) that are responsible for main-
taining the appropriate transcriptional levels of YY1. Nev-
ertheless, the mechanism of transcriptional regulation of
the YY1 gene is largely unknown so far except for a few
earlier observations on the promoter regions of the
human and mouse YY1 gene [7,8].
In the current study, we have identified a cluster of multi-
ple YY1 binding sites located in the first intron of the YY1
gene. We characterized this cluster of YY1 binding sites in
terms of evolutionary conservation and transcriptional
activity. We also tested the possibility that YY1 may be reg-
ulated through its own binding sites. For this test, we have
established and used a Tet-On inducible system, in which
we can control the cellular levels of YY1 protein. Our
results demonstrated that changes in the cellular levels of
YY1 protein affect the transcriptional levels of its own
locus, YY1, most likely through its own binding sites. This
autoregulation is regarded as a homeostatic response of
the YY1 locus to maintain the constant cellular levels of
YY1 protein.
Results
Identification of multiple YY1 binding sites in the 1st intron 
of YY1
We have identified an evolutionarily conserved region in
the 1st intron of YY1 via the ECR (Evolutionary Conserved
Region) browser, a tool for visualizing sequence compar-
ison of multiple vertebrate genomes http://
www.dcode.org[9]. As shown in Figure 1A, the genomic
sequence of the 1st exon and intron region of human YY1
was successfully aligned with those from eight different
species including tetraodon, zebrafish, frog, opossum,
cow, mouse, dog, and rhesus macaque. As expected, the
first exon (marked in blue) showed high levels of
sequence conservation. Interestingly, however, a similar
level of conservation was also detected in the beginning of
the 1st intron region (marked in salmon). We further ana-
lyzed this small region, 100 bp in length, in more detail.
As shown in Figure 1B, we manually aligned genomic
sequences derived from 11 different vertebrates: one each
from sea squirt, purple sea urchin and amphioxus, two
from each of two fish, one from frog, and five from mam-
mals. Multiple sequence alignment using ClustralW
revealed 20 to 48% sequence identity between the uro-
chordates, 71 to 82% sequence identity between the two
fish, 80 to 98% sequence identity between the five mam-
mals. Detailed inspection revealed that this small region is
mainly filled with multiple YY1 binding sites. Most verte-
brates contain 5 YY1 binding sites within this 100 bp
region except for sea squirt (3 binding sites) and amphi-
oxus (4 binding sites). Neither the sequence nor the
length of the spacer regions between individual YY1 bind-
ing sites are conserved, which becomes more apparent in
the urochordates' YY1 binding regions. The sequences of
most of the YY1 binding sites are identical to the consen-
sus sequences of the known YY1 binding motif, which dis-
play very high levels of affinity to YY1 protein [10].
However, one binding site, the 3rd one of all the verte-
brates except urochordates, shows a slight sequence varia-
tion from the known consensus (marked in green), but
still conserved among the vertebrates. The orientation of
the individual YY1 binding sites is also conserved: the first
two YY1 binding sites are localized in one direction, while
the remaining three sites are in the other direction. The
opposite orientation of the two outside YY1 binding sites
is particularly well conserved throughout all the verte-
brates. We have also examined the 1st intron of pho, a
homolog of YY1 in Drosophila [11], but we did not find a
similar genomic region with multiple Pho-binding sites.
This indicates that this cluster of YY1 binding sites is
unique to vertebrates. Chromatin immunoprecipitation
(ChIP) assay was performed to confirm the in vivo binding
of YY1 to its own binding sites located in the 1st intron.
Homogenized mouse brain tissues were cross-linked with
formaldehyde and immuno-precipitated with anti-YY1
polyclonal antibodies (Figure 1C). As expected, the multi-
ple YY1 binding sites showed consistent enrichment levels
of the immuno-precipitated DNA with this ChIP experi-
ment, whereas the two other control regions, upstream
and downstream, did not show any detectible levels of the
DNA enrichment. This confirms in vivo binding of YY1 to
its own multiple binding sites in the 1st intron. In sum, the
1st intron of the YY1 gene locus of all vertebrates contains
a cluster of its own DNA-binding sites.
YY1 binding sites as a transcriptional activator for YY1 
transcription
We performed promoter assays to determine potential
roles of this cluster of YY1 binding sites in YY1 transcrip-
tion. For this experiment, we first tried to clone and
manipulate the 1-kb genomic region surrounding the 1st
exon of the mouse YY1, but we could not amplify and sta-
bly maintain this fragment in bacterial clones mainly due
to the unusually high GC composition of this region,
around 80%. Therefore, we used the homologous region
derived from zebrafish. According to a series of initial pre-
tests (data not shown), the promoter region of the
zebrafish YY1 has reasonably high levels of promoter
activity in several mouse cell lines, confirming the feasibil-
ity of the planned experiments as well as the evolutionary
conservation of the promoter activity associated with this
genomic region.BMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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Evolutionary conservation of the YY1 binding sites in the 1st intron of YY1 Figure 1
Evolutionary conservation of the YY1 binding sites in the 1st intron of YY1. The ECR (Evolutionary Conserved 
Region) browser shows that the 1st exon and the beginning region of the 1st intron of YY1 are well conserved among eight spe-
cies: tetraodon, zebrafish, frog, opossum, cow, mouse, dog, and rhesus macaque. Human YY1 was used as a reference 
sequence for this alignment. The height of the graph peaks indicate the level of nucleotide identity, while blue and salmon 
colors indicate exon and intron regions, respectively (A). The genomic sequences of the 1st intron of YY1 from 11 different 
species were also manually aligned: one each from purple sea urchin, sea squirt and amphioxus, two from each of two fish, one 
from frog, and five from mammals. The YY1 binding sequences marked in blue and green indicate the perfectly and imperfectly-
matched YY1 binding sequences, respectively. The arrows on the right side of the sequences or under the YY1 binding 
sequences indicate the orientation of individual YY1 binding sites (B). The genomic region surrounding the five YY1 binding 
sites located within the 1st intron of mouse YY1. The YY1 binding sites are indicated by thick arrows with orientations, while 
the 1st exon by a closed rectangle. The thin arrows underneath the genomic layout indicate the position and direction of 
primer sets used for the PCR amplification of ChIP DNAs. The amplified PCR products of each region are shown as the follow-
ing order: Input (lane 1), the ChIP DNA with rabbit normal serum (lane 2), and the ChIP DNA with YY1 antibody (lane 3) (C).BMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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We have generated a series of 12 different constructs by
modifying the 1.1-kb endogenous promoter region of the
zebrafish YY1. The 1.1-kb region, covering the 1st exon
and the multiple YY1 binding sites, was first subcloned
into a promoterless reporter system, IRES-β-Geo (Figure
2). Each of these constructs differs from the others in
binding affinity, orientation and numbers of intact YY1
binding sites. This series of promoter assays excluded one
particular YY1 binding site, the third, that imperfectly
matches the YY1 consensus sequence (GCCATAnT instead
of GCCATnTT). This difference is known to have much
weaker binding affinity to YY1 protein [12]. To lower the
DNA-binding affinity to the protein, the sequences of the
4 remaining YY1 binding sites were mutated from (A/
C)GCCATnTT to AACCATnTT (Construct named as Low
affinity). The orientation of YY1 binding sites was also
reversed in an opposite direction (Constructs named as
Forward, Reverse and Both in Figure 2A). We also com-
pletely abrogated the binding potential of individual YY1
binding sites through mutating the three critical bases
The cluster of YY1 binding sites as a transcriptional activator Figure 2
The cluster of YY1 binding sites as a transcriptional activator. The schematic diagram shows the promoter region of 
the zebrafish YY1 containing the 1st exon and 4 perfect-matched YY1 binding sites (arrows). This promoter region was sub-
cloned into the IRES-β-Geo promoterless vector, and subsequently modified to change the binding affinity and orientation of 
individual YY1 binding sites (A). Open arrows indicate the intact YY1 binding sites, while the gray arrows indicate the YY1 
binding sites with lower affinity to the YY1 protein. All the YY1 binding sites in the Low affinity construct were modified from 
(A/C)GCCATnTT to AACCATnTT. The orientation of the YY1 binding sites marked by closed arrows is reversed with 
respect to the endogenous binding sites. The Forward construct has all binding sites in the forward direction; the Reverse con-
struct has all in a reverse direction; and the Both construct contains both pairs in a reverse direction. The binding potential of 
these sites was also completely abolished through changing from GCCATnTT to ATTATnTT (B). The numbers in the name of 
each construct indicate the position of mutated YY1 binding site. The promoter activity of each construct was analyzed more 
than three times, and the averaged value is shown along with S.D. (Standard Deviation). The averaged value for each construct 
was further compared with that of the Control construct. These promoter assays were performed using two different cell 
lines, Neuro2A and NIH3T3. Only the result set from the Neuro2A cell line is shown in graphs since the result set derived 
from NIH3T3 showed almost identical patterns.BMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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within the core motif of YY1 from GCCATnTT to ATTAT-
nTT (Constructs named as 1 mut, 12 mut, 123 mut, All
mut, 4 mut, 34 mut and 234 mut in Figure 2B). These con-
structs were individually transfected into two different cell
lines, Neuro2A and NIH3T3, along with an internal con-
trol luciferase vector (pGL3 control) to normalize the β-
gal activity.
As shown in Figure 2A and 2B, the normalized transcrip-
tional activity of each construct was compared to the activ-
ity of the control construct containing the original
unchanged 1.1-kb genomic region of the zebrafish YY1.
The promoter activities of all the mutant constructs
showed a dramatic decrease compared to that of the con-
trol construct. The original activity was completely abol-
ished by any change affecting the binding affinity or
orientation of the intact YY1 binding sites (Figure 2A).
This is also true for the second series of mutant constructs
containing the different numbers of intact YY1 binding
sites. Regardless how many and which positions of YY1
binding sites remain, a single change affecting any of the
YY1 binding sites completely abolished the transcrip-
tional activity of the YY1 promoter (Figure 2B). This indi-
cates that all these YY1 binding sites are absolutely
required for the transcriptional activity of the YY1 pro-
moter. A similar pattern was also consistently observed in
both Neuro2A and NIH3T3 cells. In sum, the YY1 binding
sites function as a transcriptional activator for the YY1
promoter, and this role apparently requires the absolutely
intact sequence structure of all the YY1 binding sites.
Homeostatic control of the cellular levels of YY1 protein
The identification of the YY1 binding sites within the YY1
locus hinted at one intriguing possibility: YY1 may con-
trol its own transcription rate through its own binding
sites. To test this possibility, we first set up an in vitro sys-
tem in which we can control the cellular levels of YY1 pro-
tein. Briefly, human YY1 was added into the mouse cell
line Neuro2A, and used as an exogenous gene, which
allows for easy distinction between the exogenous and
endogenous YY1. A Tet-On inducible system was
employed to control the expression of the human YY1.
We have successfully established several stable cell lines
that can induce transcription of the human YY1 by the
administration of an inducer, Doxycycline (Tet-On
Advanced system) [13]. More detailed information is
described in Methods.
With the three selected stable cell lines, we first performed
time-course experiments (Figure 3A). All three cells
showed increased levels, about 5 fold, of YY1 protein at 24
and 48 hours after the Dox administration as shown on
western blot results. With the same set of cells, we further
confirmed this induction at the transcription level by per-
forming RT-PCR, in which we can differentiate the
induced human YY1 from the endogenous mouse YY1
(Figure 3B). As expected, we observed a dramatic increase
in the transcriptional level of human YY1 at 24 and 48
hours after the Dox administration. Although we
observed low levels of the human YY1 prior to the Dox
induction, this is believed to have been caused by
genomic DNA contamination in the RNA samples. Inter-
estingly, the transcriptional levels of the endogenous YY1
progressively decreased during the induction. Another
independent measure using qRT-PCR further revealed
that the transcriptional levels were reduced to 70% at 24
hours and to 50% levels at 48 hours, respectively. Accord-
ing to our survey on the transcription levels of other genes
(Peg3, Usp29, Nespas, Nesp, Xist, and p53), the observed
down-regulation was specific to the YY1 locus (data not
shown). This indicates that the overall increased levels of
YY1 protein, through the induction of the exogenous YY1,
somehow resulted in reduction in the transcriptional lev-
els of the endogenous YY1. This initial observation was
further validated through the following scheme. We first
increased the overall levels of YY1 protein through the
induction of the human YY1, and later reversed the
increased levels back to the normal levels of YY1 protein
by withdrawing the inducer, Dox, from culture media. As
predicted, this cycle of addition and withdrawal of the
Dox treatment caused a concurrent rise and fall in the
overall levels of YY1 protein. The levels of endogenous
YY1 transcription changed in a manner inverse to the
induced YY1 protein: decreasing with YY1 induction and
increasing with removal of YY1 induction as shown in the
results of qRT-PCR (Figure 3C). This inverse pattern is
thought to be a counter-balancing response from the
endogenous YY1 locus to maintain constant cellular levels
of YY1 protein. In sum, these results confirm that the over-
all cellular levels of YY1 protein can affect the transcrip-
tion levels of the YY1 locus.
YY1 is autoregulated through its own binding sites
The above results clearly demonstrated that the endog-
enous locus of YY1 has an unknown feedback regulatory
mechanism that maintains homeostasis of the YY1 pro-
tein levels. We next tested if this observed regulation is
indeed mediated through its own DNA-binding sites as
part of the hypothesized autoregulation. For this test, we
analyzed transcriptional responses from the YY1 pro-
moter against a background of fluctuating cellular levels
of YY1 protein. We first set up the two different cellular
levels of YY1 protein with the following scheme (Figure
4). The cells to be transfected were first incubated in the
absence (A) and presence (B) of Dox prior to transfection
experiments. During the transfection, Dox was added (A)
and removed (B) to create higher and lower levels of YY1
protein relative to the control cell, respectively. Then, the
actual transfection into these cells used each of the follow-
ing two reporters, Intact and All-mut constructs, contain-
ing the promoter region of the zebrafish YY1 with the
intact and mutated YY1 binding sites, respectively (FigureBMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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4). These individual transfections were also normalized
by including the control luciferase vector (pGL3 control).
In the first condition (Figure 4A), the promoter activity
was measured while the cellular levels of YY1 protein were
being increased by the Dox induction. As shown in Figure
4A, the Intact construct (containing the YY1 binding sites)
showed a 0.5-fold decrease in the promoter activity when
the cells started producing more YY1 protein. We also
observed a similar down-regulation from the endogenous
locus in response to increased levels of YY1 protein (Fig-
ure 3). This response, however, was not detected in the
All-mut construct (containing the mutated YY1 binding
sites), confirming that the observed response was medi-
ated through the YY1 binding sites. In the second condi-
tion (Figure 4B), the promoter activity was measured
while the cellular levels of YY1 protein were decreased by
the Dox withdrawal. The Intact construct showed in a 1.7-
fold increase in the promoter activity when the cells
started producing less YY1 protein. This is also reminis-
cent of an observed up-regulation from the endogenous
locus of YY1 in response to the decreased levels of YY1
protein. Collectively, the zebrafish YY1 promoter and the
endogenous locus of YY1 responded very similarly to fluc-
tuating levels of YY1 protein. These similar responses
agree very well with the initial prediction that the cluster
of YY1 binding sites most likely mediates the hypothe-
sized autoregulation mechanism for the endogenous
locus of YY1.
Homeostatic responses of the YY1 locus against the fluctuating levels of YY1 protein Figure 3
Homeostatic responses of the YY1 locus against the fluctuating levels of YY1 protein. A Tet-On induction system 
over-expressing human YY1 was established to control the cellular levels of YY1 protein in the Neuro2A cell line. Three stable 
YY1 inducible clones (#7, #16 and #17) were analyzed to determine the overall levels of YY1 protein at 0, 24 and 48 hours 
after the treatment of 1 ug/ml Dox with western blot analyses using YY1 and GAPDH antibodies (A). RT-PCR and quantitative 
RT-PCR were performed using total RNAs isolated from the same cell set as used in the above. The primer sets for RT-PCR 
were designed to distinguish between endogenous mouse and exogenous human YY1 (B). The transcriptional response from 
the endogenous mouse YY1 was further analyzed using a scheme which allows a cycle of up and down regulation of the human 
YY1 through Dox administration and withdrawal, respectively (C). Western blot analysis showed the concurrent up and down 
regulated levels of YY1 protein. Following RT-PCR and qRT-PCR also confirmed this pattern in the exogenous human YY1. As 
predicted, the endogenous mouse YY1 showed an opposite pattern: the down and up-regulation in response to the increased 
and decreased overall levels of YY1 protein.BMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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Discussion
The current study reports the three unique features associ-
ated with the cluster of YY1 binding sites that is localized
in the 1st intron of the vertebrate YY1 locus. First, this clus-
ter of YY1 binding sites are well conserved throughout all
the vertebrates including urochordates, suggesting that
this small region has been functionally selected in the past
500 to 600 million years (Figure 1). This region is proba-
bly one of the oldest cis-regulatory regions in the verte-
brate genomes. However, similar regions are not found in
the pho locus, the YY1 homolog in flying insects, suggest-
ing the formation of this region after the divergence of ver-
tebrates and invertebrates. This sudden formation of this
region in the vertebrates' YY1 locus may be linked to the
different expression profiles of this gene between these
two groups of animals. In insects, the homeotic genes
including pho are transiently expressed by segmentation
genes during early embryonic development, and their
later expressions are controlled by two groups of genes,
the trithorax group (trxG) and the Polycomb group (PcG)
[14,15]. Therefore, the expression pattern of pho may be
restricted and focused in a developmental stage-specific
manner. In contrast, YY1 is expressed ubiquitously, spa-
tially and temporarily [16]. The ubiquitous expression
may have allowed YY1 to be involved in a greater number
of genes and pathways in the vertebrates than in the inver-
tebrates. Consequently, the involvement in a large
number of genes most likely has necessitated more
sophisticated regulation mechanism(s) for the mainte-
nance of appropriate cellular levels of YY1. Taken
together, the cluster of YY1 binding sites most likely has
coevolved with the ubiquitous expression pattern of YY1.
The second unusual feature is that this conserved cis-regu-
latory region has the DNA-binding sites for its own pro-
tein product, YY1. This immediately suggests a potential
autoregulation mechanism for this locus. According to
our cell line studies, the cellular levels of YY1 protein
indeed affected the transcriptional levels of its own gene
locus (Figure 3), and this control also appeared to be
mediated through the cluster of YY1 binding sites (Figure
4). Besides being part of this predicted autoregulation, the
cluster of YY1 binding sites is also regarded as a transcrip-
tional activator (Figure 2) or repressor (Figure 3 and 4).
Any mutations in the YY1 binding sites caused a dramatic
decrease in the transcriptional activity of the YY1 pro-
YY1 is autoregulated through its own binding sites Figure 4
YY1 is autoregulated through its own binding sites. To demonstrate autoregulation through YY1's internal binding sites, 
we have analyzed the transcriptional activity of the zebrafish YY1 promoter with/without the YY1 binding sites at the two dif-
ferent cellular level of YY1 protein. These different conditions were set up using a Tet-On induction system over-expressing 
exogenous YY1. Before the transfection, the cell line was incubated in the absence (A) and presence (B) of the inducer, Dox. 
During transfection, Dox was added (A) and removed (B) to make the YY1 protein levels higher and lower, respectively, that 
the control cell line. Two constructs, Control and All mut, were individually transfected into the two different inducible cell 
lines, #7 and #16, along with the internal control luciferase vector (pGL3 control) in order to normalize β-gal activity.BMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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moter, indicating that YY1 is required for the transcription
of its own locus. On the other hand, the same cluster of
YY1 binding sites functions as a repressor in the presence
of excessive cellular levels of YY1 protein. According to
surveys on transcriptional regulatory networks [17], many
E coli proteins, especially repressors, are also subject to
similar autoregulation. Furthermore, the observed
autoregulation is similarly 'negative' autoregulation: these
repressors start repressing their own loci once their pro-
tein levels reach at their threshold levels. Despite these
similarities, however, it is important to note that this clus-
ter of YY1 binding sites has dual roles, repressor and acti-
vator. Interestingly, these roles have been detected at
different cellular conditions: an activator role during the
promoter assays with a normal level of YY1 protein (Fig-
ure 2) while a repressor role during YY1 induction with
higher levels of YY1 protein (Figure 3 and 4). This suggests
that the available cellular levels of YY1 protein may be a
factor deciding which of the two roles to be exerted for a
given condition.
Then, the next question is how this cluster of YY1 binding
sites knows different cellular conditions and selects a role
between an activator and repressor function. This ques-
tion may be related to the third feature of this cluster of
YY1 binding sites: multiplicity. One plausible scenario
would be that the cluster of YY1 binding sites could func-
tion as a sensor recognizing the cellular levels of YY1 pro-
tein. In the case of higher-than-normal YY1 levels, all of
the YY1 binding sites would be filled with the YY1 pro-
tein, subsequently block the traverse of this region by Pol
II polymerase, and thus function as a repressor. In the case
of lower-than-normal YY1 levels, on the other hand, only
one or two YY1 binding sites would be filled, subse-
quently stimulating transcription by Pol II, and thus act as
an activator. It will be very interesting to test this possibil-
ity in the near future, but the multiplicity and evolution-
ary conservation associated with the YY1 binding sites are
very unusual, and clearly suggest some unknown func-
tional roles in this regulatory region.
Despite a large number of genes that are controlled by
YY1, there have not been a lot of studies on the transcrip-
tional control of YY1 itself. Although the current study has
mainly focused on the predicted autoregulation mecha-
nism that might be mediated through the cluster of YY1
binding sites, we believe that this is not the only regula-
tory mechanism responsible for the YY1 transcription.
Also, we cannot rule out the possibility that the identified
cluster of YY1 binding sites might be designed for some
other functions for the YY1 locus, such as a targeting site
for epigenetic modification or a promoter for some
unknown transcripts. In a similar line, it is important to
emphasize the fact that the unusually high levels of YY1
protein are often observed in normal and cancer cells [3].
The up-regulated YY1 levels in normal cells may be an
outcome of an independent regulatory program that has
been preset in a given cell. On the other hand, the unusu-
ally high levels of YY1 protein observed in cancer cells
might be an outcome of mis-regulated YY1 transcription.
One intriguing possibility would be that some epigenetic
changes, such as DNA methylation or histone modifica-
tion, and subsequent malfunction of the cluster of YY1
binding sites might be responsible for this mis-regulation.
In that regard, it will be interesting to test the epigenetic
modification of this region in cancer cells. Overall, the
cluster of YY1 binding sites described in the current study
represents a very unique example of eukaryotic cis-regula-
tory region.
Conclusion
The current study has identified a very unusual cluster of
YY1 binding sites within its own gene locus, prompting a
potential autoregulation mechanism for YY1 transcrip-
tion. Consistently, the overall cellular levels of YY1 pro-
tein were shown to affect (or control) the transcription
levels of the endogenous YY1 locus. Also, this control
appears to be mediated through its own YY1 binding sites.
This suggests that YY1 is likely self-regulated through its
own binding sites.
Methods
Sequence alignment
The cluster of YY1 binding sites in the first intron of YY1
was discovered through the ECR (Evolutionary Conserved
Region) browser http://www.dcode.org[9]. This con-
served region was manually aligned from genomic
sequences of each genome ranging from urochordate (sea
squirt) to placental mammals. A series of database
searches were conducted using the BLAST program http://
www.ncbi.nim.gov/BLAST to obtain the genomic
sequences of the YY1 locus from several species. The
aligned sequences are as follows: sea urchin
(Scaffold81718: 20284–20353), sea squirt
(ENSCSAVG00000003120: 624148–624214), amphi-
oxus (JGI scaffold_8: 4922034–4922089), zebrafish_1
(NC_007128: 40211168–40211267), zebrafish_2
(NW_001877837: 59200–59296), fugu_1 (chrUn:
161085228–161085087), fugu_2 (chrUn: 51268538–
51268643), human (NC_000014: 99776064–
99776201), mouse (AC_000034: 110030364–
110030467), cow (NC_007319: 58875242–58875872),
dog (NW_876327: 66420933–66421058), opossum
(ENSMODG00000013124: 318625672–318625815),
and frog (JGI4.1:scaffold_222: 1017795–1034375).
ChIP assay
ChIPs were performed according to the protocol provided
by Upstate Biotechnology with some modification as
described previously [18]. Briefly, the mouse brain tissuesBMC Molecular Biology 2009, 10:85 http://www.biomedcentral.com/1471-2199/10/85
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(0.1 g per tissue) were homogenized in 10 ml PBS for
ChIP assay. The samples were treated with formaldehyde
to a final concentration of 1% and incubated at 37°C for
10 min. Treated samples were sheared by sonication to
derive DNA fragments averaging 500 bp in length.
Sheared chromatin was immunoprecipitated with anti-
YY1 antibody (sc-1703; Santa Cruz Biotechnology). Pre-
cipitated DNA and protein complexes were reverse
crosslinked and purified through phenol/chloroform
extraction. Purified DNA was used as templates for PCR
amplification. Three primer sets were used:
ChmYYup1(+), 5'-GGCACTTTTGTCACTGTTGCAC-
CGCG-3' and ChmYYup2(-), 5'-CAACTCCTCAAC-
CCCGAGCCCAGATCTC-3'; ChmYYb3(+), 5'-GGGAGCA
GAAGCAGGTGCAGATCAAG-3' and ChmYYb4(-), 5'-
CTCAACCGGCCCCGCCGCACGTCCGTTG-3'; ChmYYd
w5(+), 5'-CTGCACGGTAGGTTATCAGGAGCTGTATG-3'
and ChmYYdw6(-), 5'-CGATTCATCAACACCACACTT-
GACGAAG-3'. PCR reactions with an inclusion of 1%
DMSO were carried out for 35 cycles (94°C, 30 s; 64°C,
30 s; 72°C, 30 s) using the Maxime PCR premix kit
(Intron Biotech). The resulting PCR products were ana-
lyzed by running on 1.5% agarose gel containing ethid-
ium bromide. The animal experiment was performed in
conditions approved by the Louisiana State University
Institutional Animal Care and Use Committee (IACUC),
protocol #07–051.
Promoter assay
We used one β-Geo vector that has been modified from
pGT1.8iresβgeo [19]. We have transferred a BamHI partial
digested fragment containing the IRES-LacZ-Neo cassette
into the BamHI site of pBluescript II SK (+). All constructs
derived from zebrafish YY1 (BX546455; 5043–6110)
were cloned into the NotI site of this IRES-β-Geo vector.
Several mutations on 4 YY1 binding sites were performed
by PCR-based mutagenesis with modified oligonucle-
otides. Neuro2A and NIH3T3 cells were maintained in
MEM and DMEM medium with 10% fetal bovine serum
and 1% antibiotic-antimycotic (GibcoBRL), respectively.
2×105 cells were plated in each well of a six-well plate. On
the next day, cells were co-transfected with GeneJuice
transfection reagent according to the manufacturer's pro-
tocol (Novagen). Two days after transfection, the cells
were harvested, washed with PBS, and treated with 100 μl
of lysis buffer (0.25 M Tris-HCl, pH 7.8 + 0.1% NP40) for
30 min at 4°C and cellular debris was removed by centrif-
ugation for 10 min. For the β-galactosidase assay, 30 μl of
cell lysate was mixed with the same volume of 2× β-galac-
tosidase assay buffer (Promega) in a 96-well flat bottom
clear plate. The plate was incubated at 37°C, monitored
visually and terminated with 90 μl of 1 M sodium carbon-
ate. The absorbance was measured at 405 nm with Wallac
1420 multilabel counter VICTOR3 (PerkinElmer). For the
luciferase assay, 20 μl of cell lysate was combined with
100 μl of Luciferase Assay Reagent (Promega) in a 96-well
flat bottom white plate (Corning). Luminescence was
measured with Wallac 1420 multilabel counter VICTOR3.
To control for transfection efficiency in each well, β-galac-
tosidase activity was normalized to luciferase activity.
YY1 inducible cell line
pTet-On Advanced, pTRE-tight vectors and HeLa Tet-On
cell line were purchased from Clontech. The cDNA frag-
ments encoding human and mouse YY1 (GenBank acces-
sion No. NM_003403 and NM_009537) were inserted
into BamHI-NheI sites and BamHI-NotI sites of the pTRE-
tight vector, respectively. Neuro2A Tet-On cell line was
established by stable transfection of the pTet-On
Advanced vector under the presence of 500 ug/ml G418.
The human YY1 and mouse YY1 cloned pTRE-tight vectors
were cotransfected into Neuro2A and HeLa Tet-On cell
lines with the linearized Hygr gene at a 10:1 molar ratio,
respectively. Eight single colonies in the Neuro2A Tet-On
cell line only were isolated in the presence of 250 ug/ml
G418 and 500 ug/ml hygromycin B. The clones were ana-
lyzed to determine the cellular levels of YY1 protein by
western blot analysis after doxycycline treatment.
Western blot analysis
For our western blot analysis, the cells were lysed after dif-
ferent incubation times following doxycycline treatment
for 30 min at 4°C using lysis buffer (0.25 M Tris-HCl, pH
7.8, plus 0.1% NP-40). Cellular debris was removed by
centrifugation for 10 min. Protein concentrations were
determined by the Bradford assay kit (Pierce). Thirty
micrograms of lysate was separated on 10% SDS-PAGE
gels and transferred to PVDF membrane (Hybond-P;
Amersham) using a Mini Trans-Blot transfer cell (Bio-
Rad). Membranes were blocked for 1 h in Tris-buffered
saline containing 5% skim milk and 0.05% Tween 100
and incubated at 4°C overnight with anti-YY1 (sc-1703;
Santa Cruz Biotechnology) or anti-GAPDH (MAB374;
Chemicon) antibodies. These blots were incubated for an
additional 1 h with the secondary antibody linked to
horseradish peroxidase (Sigma). The blots were devel-
oped using a Western blot detection system according to
the manufacturer's protocol (Intron Biotech).
RT-PCR and qRT-PCR
Total RNAs were first purified from transfected cells using
Trizol as described by the manufacturer (Invitrogen); sec-
ond, first-strand cDNA was reverse transcribed using the
SuperScript First-Strand Synthesis System (Invitrogen);
and finally PCR amplifications were performed using the
following primer sets: human YY1 (hYY1F-2, 5'-GAC-
CTCTCAGATCCCAAA-3' and hYY1R-1, 5'-TTGTTTTT-
GGCCTTAGCA-3'), mouse YY1 (mYY1F-2, 5'-
GACCTCTCAGACCCTAAG-3' and mYY1R-1, 5'-
TTGTTTTTGGCTTTAGCG-3'), and mouse GAPDHPublish with BioMed Central    and   every 
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(GAPDH-RT-F, 5'-ATGACATCAAGAAGGTGGTG-3' and
GAPDH-RT-R, 5'-CATACCAGGAAATGAGCTTG-3'). Also,
quantitative real-time PCR was performed with iQ SYBR
Green Supermix (Bio-Rad) using the icycler iQ multicolor
real-time detection system (Bio-Rad). All qPCRs were car-
ried out for 40 cycles under standard PCR conditions. We
analyzed the results of quantitative real-time PCR based
on the ΔΔCt method [20].
Authors' contributions
JDK analyzed sequences and constructed all the vectors
for the promoter assays, and also performed the ChIP
experiment and wrote the paper. SY established the YY1
inducible cell lines and performed RT-PCR, western blot
and the promoter assays. JK provided the original concept
of the study, supervised the study, and contributed to writ-
ing the paper. All authors read and approved the final
manuscript.
Acknowledgements
We would like to thank Dr. Kurt Svoboda for providing zebrafish; Jennifer 
M. Huang for critical reading of the manuscript. This research was sup-
ported by National Institutes of Health R01 GM66225 (J.K).
References
1. Liu H, Shi Y: Ying Yang 1.  In Zinc Finger Proteins: From Atomic Contact
to Cellular Function Edited by: Iuchi S, Kuldell N. New York: Kluwer
Academic/Plenum; 2005:182-194. 
2. Thomas MJ, Seto E: Unlocking the mechanisms of transcription
factor YY1: are chromatin modifying enzymes the key?  Gene
1999, 236(2):197-208.
3. Gordon S, Akopyan G, Garban H, Bonavida B: Transcription factor
YY1: structure, function, and therapeutic implications in
cancer biology.  Oncogene 2006, 25(8):1125-1142.
4. He Y, Casaccia-Bonnefil P: The Yin and Yang of YY1 in the nerv-
ous system.  J Neurochem 2008, 106(4):1493-1502.
5. Schug J, Schuller W-P, Kappen C, Salbaum JM, Bucan M, Stoeckert CJ:
Promoter features related to tissue specificity as measured
by Shannon entropy.  Genome Biol 2005, 6(4):R33.
6. Calame K, Atchison M: YY1 helps to bring loose ends together.
Genes Dev 2007, 21(10):1145-1152.
7. Safrany G, Perry RP: Characterization of the mouse gene that
encodes the delta/YY1/NF-E1/UCRBP transcription factor.
Proc Natl Acad Sci USA 1993, 90(12):5559-5563.
8. Yao YL, Dupont BR, Ghosh S, Fang Y, Leach RJ, Seto E: Cloning,
chromosomal localization and promoter analysis of the
human transcription factor YY1.  Nucleic Acids Res 1998,
26(16):3776-3783.
9. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L: ECR Browser: a
tool for visualizing and accessing data from comparisons of
multiple vertebrate genomes.  Nucleic Acids Res 2004:W280-286.
10. Kim JD, Kim J: YY1's longer DNA-binding motifs.  Genomics
2009, 93(2):152-158.
11. Brown JL, Mucci D, Whiteley M, Dirksen ML, Kassis JA: The Dro-
sophila Polycomb group gene pleiohomeotic encodes a DNA
binding protein with homology to the transcription factor
YY1.  Mol Cell 1998, 1(7):1057-1064.
12. Kim JD, Faulk C, Kim J: Retroposition and evolution of the
DNA-binding motifs of YY1, YY2 and REX1.  Nucleic Acids Res
2007, 35(10):3442-3452.
13. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W:
Exploring the sequence space for tetracycline-dependent
transcriptional activators: novel mutations yield expanded
range and sensitivity.  Proc Natl Acad Sci USA 2000,
97(14):7963-7968.
14. Kwon S-H, Kim SH, Chung H-M, Girton JR, Jeon S-H: The Dro-
sophila pleiohomeotic mutation enhances the Polycomblike
and Polycomb mutant phenotypes during embryogenesis
and in the adult.  Int J Dev Biol 2003, 47(6):389-395.
15. Simon J, Chiang A, Bender W: Ten different Polycomb group
genes are required for spatial control of the abdA and AbdB
homeotic products.  Development 1992, 114(2):493-505.
16. Luo C, Lu X, Stubbs L, Kim J: Rapid evolution of a recently ret-
roposed transcription factor YY2 in mammalian genomes.
Genomics 2006, 87(3):348-355.
17. Alon U: Network motifs: theory and experimental
approaches.  Nat Rev Genet 2007, 8(6):450-461.
18. Kim J, Kollhoff A, Bergmann A, Stubbs L: Methylation-sensitive
binding of transcription factor YY1 to an insulator sequence
within the paternally expressed imprinted gene, Peg3.  Hum
Mol Genet 2003, 12(3):233-245.
19. Mountford P, Zevnik B, Duwel A, Nichols J, Li M, Dani C, Robertson
M ,  C h a m b e r s  I ,  S m i t h  A :  Dicistronic targeting constructs:
reporters and modifiers of mammalian gene expression.  Proc
Natl Acad Sci USA 1994, 91(10):4303-4307.
20. Winer J, Jung CK, Shackel I, Williams PM: Development and vali-
dation of real-time quantitative reverse transcriptase-
polymerase chain reaction for monitoring gene expression
in cardiac myocytes in vitro.  Anal Biochem 1999, 270(1):41-49.